Vericel (VCEL) Tops Q1 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Vericel Reports First-Quarter 2016 Financial Results
May 10, 2016 7:30 AM EDTTotal Revenues of $14.1 Million Reported for the Quarter
Carticel and Epicel Revenues Increase 31% versus First Quarter 2015
Conference Call Today at 8:00am Eastern Time
CAMBRIDGE, Mass., May 10, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today reported financial results for the first quarter ended March 31, 2016.
Total net revenues for the quarter ended March 31, 2016 were approximately $14.1 million and included approximately $8.8 million of Carticel net revenues and... More
